Non-alcoholic fatty liver disease comprises a spectrum of clinical and histopathological changes including 'simple' steatosis, steatosis with inflammation, steatohepatitis, cirrhosis and hepatocellular carcinoma. It was initially described in the context of drug-induced liver injury and acute liver disease following jejuno-ileal bypass surgery but since the early 1980s it has been widely acknowledged as the hepatic manifestations of the metabolic syndrome. It now represents a burgeoning public health crisis and is fast becoming the main indication for liver transplantation in some parts of the world. Its true incidence and prevalence is unknown although estimates have been made from large imaging studies. Liver biopsy interpretation is still regarded as the gold standard for making accurate diagnoses in NAFLD although sampling limitations are recognized. Furthermore, clear definitions for key histopathological components have been lacking and partly as a result of significant inter-observer variations in making a diagnosis of steatohepatitis. This review considers some aspects of classification and variant forms of NAFLD such as that occurring in children. It provides an update on grading and staging systems and histopathological prognostic factors and, finally, addresses the role of liver biopsy in contemporary clinical care of patients with NAFLD.
Introduction and historical perspective
Alcoholic liver disease (ALD) is the archetypal fatty liver disease comprising a spectrum of pathological changes from the simple accumulation of lipid in hepatocytes (steatosis) through fat and inflammation (steatohepatitis) to cirrhosis and hepatocellular carcinoma 1 .
That such a spectrum of disease could also be associated with other conditions was not widely acknowledged until the late 1970s when reports appeared of steatosis and steatohepatitis, histologically indistinguishable from that of alcoholic liver disease, occurring in patients following jejuno-ileal bypass surgery 2 , taking therapeutic agents such as perhexilene 3 and in patients that were diabetic and obese 4 Since then it is recognized that fatty liver disease (FLD) is a common phenomenon in patients with the metabolic syndrome.
As with ALD there appear to be host factors that determine the degree (if any) of liver disease with some patients with BMIs greater than 40 showing no steatosis or steatohepatitis. Initially, it was considered that fatty liver disease in the metabolic syndrome was a more indolent process than in alcoholic liver disease with relatively slow progression but metabolically associated FLD is now one of the most common indications for orthotopic transplantation in many centres around the world. Increasingly it is also being seen as the underlying aetiology in the development of hepatocellular carcinoma where it may arise before cirrhosis is established.
The incidence and prevalence of FLD has been assessed by a number of investigators but the true current and projected public health burden from this condition remains uncertain. The situation is confounded by inconsistent histopathological and clinical definitions for diagnosis and the existence of a number of semi-quantitative scoring systems to assess the extent of morphological damage. Furthermore there is often a lack of appreciation of the impact of co-morbid liver disease. This review focuses on the histopathology of non-alcoholic fatty liver disease (NAFLD) and addresses issues of classification and definitions particularly in the context of the metabolic syndrome. It also considers the place of liver biopsies in the contemporary clinical management of patients with NAFLD.
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The first use of the term "fatty liver" in the English medical literature is attributed to Thomas Addison from Newcastle upon Tyne, England 5 , better known today for the description of the eponymous disease. Several years later, Karl Rokitansky, one of the forefathers of pathology from Vienna, Austria, observed in autopsy material that fat accumulation in the liver may be aetiologically related to cirrhosis 6 . Addison and Rokitansky most likely referred to alcoholic liver disease but an association of fatty liver with obesity and starvation was made by Bartholow in 1885 7 and by Statkewitsch in 1894 8 , respectively.
Pepper (1884) 9 was first to describe fatty liver in a diabetic patient and in 1938 Charles
Connor highlighted an aetiological link and described in detail FLD and its association with cirrhosis development in diabetics 10 . 
Histopathological diagnosis of NAFLD/NASH in the setting of the metabolic syndrome

Steatosis
Hepatic steatosis refers to the accumulation of lipid droplets within hepatocytes and is considered pathological when it affects >5% of hepatocytes 11 . In adults, it usually first affects acinar zone 3 (centrilobular) hepatocytes, while in children zone 1 (periportal) predilection or a panacinar pattern is more common 13 . has recently been seen to correlate with NAFLD development. The inactive PNPLA3
accumulates on the surface of lipid droplets and is associated with an increase in macrovesicular steatosis 18 . In NAFLD, the accumulation of triacylglycerols within intracytoplasmic droplets may actually protect hepatocytes from the detrimental effect of non-droplet bound lipotoxic saturated free fatty acids 19 .
An important recent observation in NAFLD is that of reticulin loss, a finding more prominent in extensive steatosis and not related to the presence of inflammation or fibrosis 20 .
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The pathophysiological effects of disruption of the connective tissue framework of the sinusoids remain to be determined. Steatosis may not persist as NAFLD progresses and may often be absent in cirrhotic specimens.
Histological assessment of the extent of steatosis is usually semi-quantitative and is based on the percentage of hepatocyte involvement. Most commonly the affected parenchyma is divided in thirds i.e. 5-33%, 33-66%, >66% and consequently the severity of steatosis may be converted into mild, moderate or severe, respectively 21, 22 . Histopathologists have a tendency to overestimate the extent of steatosis, especially when it is severe, therefore more accurate and objective methods for its quantitation have been devised mainly based on digital image analysis (DIA) 23 . . Although, traditionally, steatosis or steatosis with inflammation were considered "innocent" and non-progressive, recent data from studies with paired liver biopsies have shown that both can progress to steatohepatitis with clinically significant fibrosis (albeit infrequently) 33, 34 .
Steatosis and fibrosis
According to traditional definitions of NAFLD, hepatocellular injury and fibrosis, considered features of progression to steatohepatitis, are not observed in steatosis injury 11, 35 . In adult NAFLD, mild fibrosis, either portal or zone 3 sinusoidal without hepatocellular injury may occasionally be encountered in cases of steatosis or steatosis with chronic inflammation. 
Steatohepatitis
It is important to draw a distinction between steatosis with mild inflammation and steatohepatitis. Most experts agree that the minimal requirements for the morphological diagnosis of NASH includes hepatocyte ballooning in addition to steatosis and inflammation 36, 37 . These key lesions are typically accentuated in zone 3 of the hepatic acinus. None of the single morphological features described above is specific for NASH (see below). Importantly, there is a very marked overlap of the morphological spectrum of NAFLD and ALD. Therefore, significant alcohol consumption has to be excluded in order to warrant a diagnosis of NASH. However, there is no universally accepted threshold that allows for the definition of excess alcohol consumption and indication that fatty liver disease in a given patient is related to alcohol rather than insulin resistance. Data range between 10-20 g/day for women and 20-40 g/day for men [45] [46] [47] [48] [49] . Furthermore ALD and NAFLD share obesity and overweight as risk factors 50, 51 . Both conditions can co-exist and aggravate liver injury 52 . The distinction between ASH and NASH may be very difficult or impossible on morphological grounds in an individual patient.
The histological diagnosis of NASH has important clinical and prognostic implications. However, intra-and inter-observer variability in the interpretation of the morphological key features of NASH have been noted as important limitations of the utility of liver biopsy in assessing severity of disease 35, 53, 54 . In general, intra-observer variation is lower than inter-observer variation. While substantial agreement for steatosis was reported in two studies, the strength of inter-observer agreement for inflammation and ballooning were only fair to moderate 22, 55 . However, it should be noted that substantial inter-observer agreement has been found in a more recent study 56 . There is some evidence that the use of immunohistochemistry may facilitate the identification of morphological features, reducing the level of inter-observer variation. This particularly applies to the detection and quantification of ballooning, a morphologically ill-defined feature of hepatocellular injury that may be discrete in mild NASH 35 and that is also a feature of several liver diseases including acute and chronic viral and autoimmune hepatitis, chronic cholestasis, copper toxicity, and ischemia-reperfusion injury in the liver allograft. Significant diminution or loss of immunohistochemically demonstrable cytoplasmic expression of K8/18 42 is only a feature in steatohepatitis, cholate stasis, copper toxicity and ischaemia-reperfusion injury. Therefore, loss of cytoplasmic K8/18 immunohistochemical staining can be regarded a marker for a certain type of hepatocellular injury and is useful in objectively detecting ballooned cells with higher sensitivity than conventional H&E histology in NAFLD 57 . In addition, presence of small MDB is easily appreciated by p62 and ubiquitin immunohistochemistry 58, 59 . The presence of MDB and expression of Shh in ballooned hepatocytes have been shown to correlate with severity of NASH and disease progression 60, 61 .
Although initially considered a disease confined to affluent industrialised Western countries, obesity and insulin resistance are not restricted to the West and over the past two decades there has been a substantial increase in the prevalence of the metabolic syndrome in the Asia-Pacific region and developing nations in other continents 62 . Interestingly, only around 3% of Asians are classified as obese using a BMI cut-off of 30; it is recognised that obesity-related metabolic disorders occur at lower body weight than in Caucasians 63 . Some studies have estimated the incidence of NAFLD to be around 15% in China 64 but extensive natural history studies are not available form that region. Despite the clinical differences between Western NAFLD and Asian NAFLD there is no current evidence to suggest that the histopathological features differ although to our knowledge this has not been comprehensively studied.
Diagnosis of NAFLD/NASH in other disease settings
Several therapeutic agents are known to be associated with liver injury resembling morphological changes typically occurring in NAFLD/NASH (termed chemotherapy-or drugassociated steatohepatitis, CASH or DASH, respectively) [65] [66] [67] and have the potential to progress to cirrhosis and portal hypertension 68 . The morphological features of drug-or chemotherapy-associated fatty liver disease broadly resemble that of metabolic syndromeassociated NAFLD but their location within the hepatic acinus may differ from adult metabolic syndrome-associated NAFLD that has a zone 3 accentuation pattern of injury. For example, ballooned hepatocytes may occur in a periportal distribution in amiodaroneinduced hepatotoxicity. Moreover other drug-related changes including phospholipidosis or veno-occlusive disease 69 may also be present along with features resembling NAFLD. While a large number of drugs can cause steatosis (reviewed in 70 ), DASH/CASH is a relatively rare phenomenon. However, DASH/CASH due to amiodarone and irinotecan is well described 71 .
Moreover, several steatogenic drugs such as tamoxifen, oestrogenic drugs and nifedipine may precipitate or exacerbate steatohepatitis in the presence of other risk factors. CASH in the setting of irinotecan treatment of liver metastases from colorectal cancer is associated with an adverse prognosis 66, 72 , particularly in patients with pre-existing liver damage 72 . Other causes of steatosis and steatohepatitis including those secondary to gastrointestinal bypass surgery, exogenous toxins and inherited metabolic disorders were reviewed by 73 .
Criteria for diagnosing NAFLD/NASH with concurrent disease
Given the high prevalence of NAFLD related to insulin resistance and/or the metabolic syndrome in Western populations, histological evidence of concurrent NAFLD and other liver disease, such as chronic hepatitis B (CHB) and C (CHC) [74] [75] [76] , human immunodeficiency virus (HIV) infection 77 , autoimmune hepatitis [78] [79] [80] , biliary disease 81, 82 or inherited metabolic liver disease 83 is a relatively frequent finding 52, 53, 84, 85 . In some but not all liver diseases concurrent NAFLD appears to aggravate liver injury and fibrosis progression [75] [76] [77] 85, 86 . However, some diseases by themselves may be causally related to fatty liver development independently from insulin-resistance. Some of the more frequent ones include ALD, CHC, and drug induced liver injury (DILI). In such cases it is difficult to ascertain whether the concurrent condition leads to de novo steatosis or steatohepatitis or whether it exacerbates underlying NAFLD 70, 87 .
Fatty change of hepatocytes in CHC can be found in 40-86% of cases, depending on the viral genotype 88 . Steatosis in CHC cases may be due to virus-related insulin resistance or -in genotype 3 infections -to direct viral effects on hepatocellular lipid metabolism 89 .
Acinar inflammation is frequently present in CHC. However, there is no convincing evidence that CHC per se can lead to the form of ballooning seen in steatohepatitis, accompanied by MDB formation and pericellular fibrosis. Therefore, the diagnosis of NASH in CHC, as well as in most other liver diseases, is reliably achieved by these findings, provided that ALD can be excluded on clinical grounds. In CHC, NASH preferentially develops in cases with severe steatosis, and genotype 3 infection independently from the metabolic syndrome 90 .
Histological evidence of NAFLD in CHC 90 has been associated with a higher fibrosis stage, impaired treatment response to interferons and ribavirin and an increased risk of HCC in most studies 76, 91 . It is not yet clear whether fatty change and/or NASH impact on the efficacy of newer protease-inhibitor based antiviral therapies 49 . NAFLD in CHB is associated with metabolic host factors and is not related to increased risk of fibrosis or acceleration of disease progression 92, 93 .
Concurrence of ALD and NAFLD is probably not rare and is thought to promote liver injury and fibrogenesis. Although the spectrum of morphological lesions of ALD and NAFLD shows broad overlap 94 there are several histological changes that occur in ALD-associated liver damage that have not been described in NAFLD and may thus serve as indicators that the FLD may be alcohol-related. These include obliterative lesions of the terminal hepatic venules, canalicular cholestasis, alcoholic foamy degeneration, marked portal and/or acinar infiltration by neutrophils, and marked ductular reaction and cholangiolitis 35 .
Histological definitions and classification
Although steatosis, steatosis with inflammation, NASH and cirrhotic NAFLD are considered components of a continuous spectrum, the initial concept of a two-hit phenomenon 95 whereby lipid accumulation is the first event in the pathogenesis of the disease while inflammatory mediators, endotoxin, mitochondrial dysfunction and ER stress represent a second stage which is a prerequisite for NASH development has recently been challenged.
Many authorities now subscribe to a multiple, parallel-hit hypothesis 96 . Recent evidence suggests that free fatty acids (FFA) and their metabolites may be major factors in the pathogenesis of NASH 97 and indeed there is evidence that triglyceride accumulation, the principal event in steatosis, by be a protective phenomenon as a sink for the more toxic . This has led some to believe that steatosis and steatohepatitis may not be parts of a linear spectrum of NAFLD but rather discrete entities 98 . Against this, however, are observations that NAFLD can regress either spontaneously or following therapeutic intervention and that in some cases there is not only a reduction in grade but even resolution of NASH 35 .
Irrespective of whether the lesions are part of a continuum or distinct entities followup studies (discussed below) underline the need for an accurate diagnosis of NASH. Central
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to this is recognition of the presence of ballooning. In the absence of immunohistochemistry this relies on sometimes-subtle changes by microscopy with clarification of the cytoplasm of hepatocytes and accentuation of the cell borders. The inter-observer reproducibility of identifying ballooning among general pathologists is at best moderate but in our opinion this has been contributed to by imperfect definitions. While it has been said that balloons may come in all shapes and sizes, reproducibility is likely to be considerably improved if enlargement of the cell is considered a pre-requisite for the identification of ballooning. In our respective referral practices we have frequently encountered over-diagnosis of NASH in cases in which there has been steatosis and chronic inflammation but where cytoplasmic glycogenosis has been mistaken for ballooning. Some pathologists use the term borderline NASH to describe cases that fall into this category; we would discourage the use of this misleading term.
Another area that requires further consideration is the definition of steatosis itself. In all recent scoring systems >5% is regarded as the cut-off for making a diagnosis. This however was based on early biochemical studies that indicated that normal liver contained 5% lipid by weight reviewed by 99 . Adoption of this into histopathological definitions is somewhat arbitrary. A further pitfall is that not all papers have clearly defined whether it is 5% of area containing fat or 5% of hepatocytes. A similar argument about arbitrary cut-off levels could be made for the definition of mild, moderate and severe steatosis.
The NAFLD field has to some extent been plagued by the use of abundant terms and descriptors. Some authors have argued that non-alcoholic fatty liver disease is a misnomer and that it should be described using a positive criterion 100 . We agree with this and our preference in assessing biopsies from patients with fatty liver disease is to follow the approach taken in viral hepatitis which (i) to identify the principal lesion i.e. steatosis (+/-inflammation) or steatohepatitis (ii) if steatohepatitis, then include an assessment of grade and stage (see below) and (iii) description of the known aetiology when available. The latter we would suggest should be one of the following: alcoholic, metabolic, mixed alcoholic/metabolic, drug/toxin-related or jejuno-ileal bypass surgery-related.
Paediatric NAFLD
NAFLD is the most common cause of steatosis in liver biopsies of children and adolescents followed by the effects of inherited metabolic disorders, cancer, and hepatitis C 101 . The increased prevalence of paediatric NAFLD (2.6%-7.1% in population-based studies and 0.7%-17.3% in autopsy studies) reflects the increase in prevalence of overweight and obesity in children over the last two decades, and it is linked with the development of the metabolic syndrome and its consequences Since the prototypic study of Schwimmer et al 107 which highlighted histological differences between paediatric and adult NAFLD, several studies from different countries have confirmed that liver biopsies from children with NAFLD show more prominent portalbased chronic inflammation and fibrosis; more severe steatosis (panacinar or with a zone 1 predilection), less frequent hepatocyte ballooning and MDBs, and less commonly zone 3 sinusoidal fibrosis [108] [109] [110] . Schwimmer et al first used the term "paediatric-type" or "type 2"
NAFLD for this constellation of predominantly zone-1 based lesions in paediatric liver (51% of the 100 cases studied) in contrast to the less frequent (17%) zone-3 based histologic pattern "adult type " or "type 1" NAFLD. Type 2 NAFLD was thought to be more common in older boys of non-white ethnicity 107 . However, it was shown in subsequent studies that most cases (up to 82%) have overlapping features Recently, a histological scoring system for grading activity in paediatric NAFLD has been developed and validated taking into account portal-based inflammation in addition to steatosis, acinar inflammation and ballooning 114 . The new score showed an excellent correlation with a global histological diagnosis NASH but its value in routine practice remains to be determined.
Grading and staging of NAFLD
Evaluation of morphological features of NAFLD by semi-quantitative scoring is frequently performed to provide global and standardized assessment of grade of disease activity and stage of fibrosis for use in clinical trials and to support of clinical decision making 22, 56, 60, 115, 116 .
One of the currently most widely used measures of grade, the NAFLD activity score (NAS) 22 , was developed by the NASH CRN 117 . This was based on a revision of the first grading system for NAFLD described by Brunt et al 60 .
The NAS is derived from the sum of semi-quantitative numerical scores applied to steatosis (0-3), hepatocellular ballooning (0-2) and acinar (lobular) inflammation (0-3) which can range from 0-8 (Table 1) . At thresholds of <3 and ≥5 the NAS showed good correlation with the histological diagnoses not NASH and NASH, respectively (22) . However, the sensitivity and specificity of the NAS for a histological diagnosis of NASH at a threshold level of ≥5 is 57% and 95%, respectively 118 . The NAS cannot therefore be used (and indeed was never intended) to replace the histopathological classification of NAFLD types (i.e. steatosis versus NASH). Instead, the NAS is designed for use in clinical trials to reflect changes in individual histological key features of NASH.
Interestingly, in contrast to fibrosis stage, NAS did not correlate with prognosis (liver-related death) in a recent study 115 . The NAS system has been externally validated 118 and is currently among the most widely used. The CRN also issued a scoring system for the evaluation of fibrosis stage 22 . As in chronic viral hepatitis scoring systems, fibrosis is assessed independently from grade 119 .
Recently, a simple histological algorithm based on a scoring system for NAFLD was developed by the European Fatty Liver Inhibition of Progression (FLIP) consortium in an attempt to standardize and limit inter-observer-related variation in the histological diagnosis of NASH (Table 1 The prognostic utility of this simple morphological classification system of NAFLD and the prognostic impact of fibrosis stage was re-evaluated and confirmed in a recent study 115 .
However, several shortcomings inherent to any scoring system have to be considered. First, not all morphological features of injury can be accounted for. Several histological changes may provide important information with respect to prognosis (see below). Any scoring-based classification developed with simplicity and applicability in mind will not cover the whole range of complexity of the disease. Numeric score-based classification cannot therefore replace the descriptive interpretation of biopsy findings 22, 56 .
Secondly, interpretation of morphological features of NAFLD is prone to observer-related variation 22, 55, 56 . As noted above, this has been shown for some of the individual parameters of NAFLD scoring systems and is even more pronounced for the diagnosis of the different NAFLD types. In this respect the FLIP algorithm has been shown to significantly reduce the inter-observer bias of the diagnosis of NASH among expert hepatopathologists as well as for general pathologists trained in liver pathology 56 .
Despite efforts to ensure standardized and reproducible classification of NAFLD some observer-related bias will most likely remain. DIA allows for quantitative assessment of morphological features in histological sections. Although investigated in more detail for CHC 121, 122 , DIA could become a useful technique to overcome this obstacle in NAFLD. For example, DIA has been shown to unveil erroneous estimation of the extent of steatosis by conventional histology in NAFLD 23, 123 . While several reports relate to the role of DIA for quantification of steatosis only few studies have addressed the impact of DIA-assisted quantification of fibrosis or inflammation on semi-quantitative scoring or correlation with noninvasive methods like radiological fibrosis estimates and/or biochemical parameters/scores in NAFLD.
Prognostic lesions in NAFLD/NASH
Histological lesions of prognostic relevance
Results from several studies have indicated that in patients with steatosis with or without inflammatory acinar changes, NAFLD will follow a benign course with low probability to progress to NASH and/or fibrosis [124] [125] [126] . However, as mentioned above, recently it has been shown that both steatosis and steatosis with inflammation can infrequently progress to steatohepatitis with clinically significant fibrosis 33, 34 .
In contrast, histological NASH distinguished from steatosis with inflammation by the presence of hepatocellular ballooning has been shown to carry substantial potential for progression This is evident from the seminal work of Matteoni et al described above 120 . The prognostic relevance of this classification system was recently confirmed 115 . Furthermore, elevated mortality rates of NASH patients as compared to patients with steatosis were also reported by other investigators 127, 128 . Portal inflammation in NAFLD is strongly associated with disease severity (fibrosis stage) 129, 130 .
NASH is very frequently associated with fibrosis 131 . The fibrosis-promoting effect of NASH was confirmed in studies based on paired biopsies in which an increase of fibrosis stage over time was found in approximately 30-50% of NASH patients [132] [133] [134] who may thus be at risk to develop cirrhosis. Indeed, as noted earlier, NASH is thought to represent one of the main causes of cryptogenic cirrhosis which is in most cases is considered burned-out NASH 135, 136 . There is evidence to suggest that cryptogenic cirrhosis and NASH-related cirrhosis are both risk factors for the development of HCC 137, 138 . Recently, fibrosis was identified as the strongest predictor of overall and/or liver-related mortality in NAFLD 115, 139, 140 .
Novel prognostic markers -clues from immunohistochemical and experimental studies
Oxidative and ER-stress and apoptosis are among the most important mechanisms driving injury and inflammation leading to NASH which is implicated in increased inflammation and . Markers for hepatocellular ballooning may therefore be useful to identify these cells with higher sensitivity in individuals at risk for progressive disease. Furthermore, they may be helpful to detect and monitor treatment effects in clinical trials 44, 143 .
Recently, the aldose reductase AKR1B10 was found to be highly differentially expressed in steatohepatitis compared to steatosis and normal liver 144 . AKR1B10 is involved in the detoxification of toxic aldehydes which may be prevalent in liver tissue in NASH or ASH. AKR1B10 was first described in human HCC 145 . It is expressed in several human cancers 146 and may be involved in cell differentiation and proliferation 147 . AKR1B10
expression may thus be a premalignant marker in the progression of steatohepatitis to HCC.
Increased numbers of CD68-positive macrophages in hepatic acini and portal tracts are found in NASH and advanced fibrosis 130, 148, 149 An association with NASH and fibrosis was also noted for ductular reaction (DR) which is thought to represent expansion of hepatic 
Liver biopsy in NAFLD -is there a role in 2015?
A recent clinical definition of NAFLD requires (i) evidence of hepatic steatosis by histology or imaging and (ii) exclusion of other causes of fat accumulation in hepatocytes, such as significant alcohol consumption, hereditary disorders or steatogenic drugs 49 . The NAFLD spectrum is defined by morphological changes in the liver parenchyma discussed in detail above and carry increasingly adverse long-term prognosis ranging from no effects on overall survival for simple steatosis to increased mortality for NASH and cirrhosis mostly due to liver and/or cardiovascular disease 120, 151, 152 . [157] [158] [159] [160] [161] [162] .
Simple steatosis alone affects the great majority of adult patients with NAFLD 124 . A minority (10-30%) have NASH 120, 161, 163 , but this is the main progressive type of NAFLD associated with the development of fibrosis in 20-40% and cirrhosis in 20-30% of cases 120, 126, 127, 133, 164 as well as significantly higher long-term mortality 115, 139 .
In adult patients with metabolic risk factors, in particular insulin resistance, clinical management is guided by the diagnosis/exclusion of NAFLD and discrimination of the NAFLD types. The diagnosis of NAFLD is based on the presence of hepatic steatosis which may be detected by imaging methods (e.g., ultrasound or MRI or novel techniques described above in the section of Steatosis) 165 Recent technical progress has also given rise to non-invasive tools to assess fibrosis stage in NAFLD patients with good accuracy. Scores and indices such as the NAFLD fibrosis score 168, 169 or the FIB-4 index and radiological methods, in particular transient elastography (TE) have been evaluated in different cohorts of NAFLD patients. These methods have been shown to reliably exclude lower fibrosis stages and have become widely accessible in clinical practice 166, 170 .
Although new non-invasive techniques may eventually lead to a change in the role of liver biopsy, currently this is the definitive investigation for NAFLD providing at the same time information on steatosis, inflammation, hepatocellular injury, fibrosis, and concurrent liver disease. Most expert guidelines recommend liver biopsy for NAFLD patients at high risk for NASH and/or advanced fibrosis 49, 165, 171, 172 . Histological predictors of fibrosis progression have been described in longitudinal studies with sequential biopsies 127, 173 . Furthermore, it is not infrequent that NAFLD coexists with other liver diseases. In these settings clinical management is affected by potentially aggravated liver injury and accelerated disease progression 50, 85, 174, 175 . Detection of NAFLD or NASH as a coexisting condition is therefore reliably achieved by histology 84, 176, 177 and is recommended by the European guidelines on NAFLD/NASH 48 . In addition, most guidelines issued by international or national hepatological societies also consider the use of liver biopsy in suspected NAFLD patients in whom other causes of steatosis or chronic liver disease cannot be excluded on clinical grounds 178 .
There is broad agreement that liver biopsy is an important tool in clinical trials and basic research on NAFLD defining the histological type of disease as well as assessing liver injury and effects of intervention 37 . However, despite the utility of histological evaluation for clinical and research applications the limitations mentioned earlier have to be taken into account. These include sampling and observer-related biases which can partly be overcome by taking biopsies of adequate length (at least 16 mm) and diameter (preferable use of a 16 gauge or greater diameter needle) in similar fashion from the same liver lobe 111 , using standardized scoring systems for the interpretation of histopathological findings (described above) and/or DIA for quantitative assessment of histological features 23, 122, 179 . Besides histological evaluation, liver tissue analysis by immunohistochemistry and molecular methods has provided and is likely to continue to contribute importantly to the elucidation of mechanisms involved in pathogenesis and natural history of NAFLD (reviewed in 53 ).
However, studies evaluating the potential of these factors for clinical decision-making are rare. 
